Patient-Reported Outcomes of Adverse Events After Perioperative Chemotherapy for Breast Cancer: A Prospective Observational Study

This prospective observational study assessed adverse events (AEs) in 115 breast cancer patients undergoing perioperative chemotherapy using a patient-reported outcomes (PRO)-based questionnaire. The study found that while gastrointestinal symptoms decreased 6 months post-chemotherapy, several AEs such as neuropathy, dysgeusia, insomnia, and nail loss persisted. Notably, grade 3 neuropathy symptoms and increased nail loss were observed, with peripheral sensory neuropathy lasting longer in patients receiving anthracycline- and taxane-based regimens compared to those on docetaxel/cyclophosphamide. The study underscores the importance of PRO-based monitoring to capture persistent symptoms often underestimated in clinical practice, suggesting that structured PRO questionnaires in follow-up care are vital for optimizing supportive management.